QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
QQQ   292.30 (-1.34%)
AAPL   144.10 (-1.25%)
MSFT   243.67 (-1.81%)
META   148.44 (-2.17%)
GOOGL   97.56 (-1.82%)
AMZN   100.77 (-1.44%)
TSLA   172.68 (-2.93%)
NVDA   196.50 (-3.51%)
NIO   12.10 (-4.80%)
BABA   112.74 (-4.76%)
AMD   73.74 (-2.20%)
T   20.03 (+0.40%)
MU   62.32 (-2.43%)
F   13.05 (-1.66%)
CGC   2.89 (-1.37%)
GE   81.92 (-1.57%)
DIS   108.55 (-0.90%)
AMC   5.06 (-8.17%)
PFE   43.74 (-0.11%)
PYPL   80.78 (-1.28%)
NFLX   356.79 (-1.10%)
NASDAQ:VRTX

Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

$320.11
-1.34 (-0.42%)
(As of 01/30/2023 12:14 PM ET)
Add
Compare
Today's Range
$319.23
$322.69
50-Day Range
$283.23
$321.48
52-Week Range
$225.28
$324.75
Volume
615,052 shs
Average Volume
1.38 million shs
Market Capitalization
$82.17 billion
P/E Ratio
25.25
Dividend Yield
N/A
Price Target
$322.79

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
0.7% Upside
$322.79 Price Target
Short Interest
Healthy
1.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.11mentions of Vertex Pharmaceuticals in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$5.60 M Sold Last Quarter
Proj. Earnings Growth
5.11%
From $13.12 to $13.79 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

394th out of 1,049 stocks

Pharmaceutical Preparations Industry

189th out of 514 stocks


VRTX stock logo

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

Invest in Brooklyn Gin: Hot craft spirits opportunity
Get in on an award winning company in the fast growing craft spirits marketpixel
Invest in Brooklyn Gin: Hot craft spirits opportunity
Get in on an award winning company in the fast growing craft spirits marketpixel
5 Reasons to Buy Vertex Pharmaceuticals Now
1 Top Growth Stock Set to Crush the Market Again in 2023
2 Growth Stocks That Could Help Set You Up for Life
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Company Calendar

Last Earnings
11/02/2021
Today
1/30/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
3,900
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$322.79
High Stock Price Forecast
$374.00
Low Stock Price Forecast
$280.00
Forecasted Upside/Downside
+0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$2.34 billion
Pretax Margin
46.28%

Debt

Sales & Book Value

Annual Sales
$7.57 billion
Cash Flow
$12.58 per share
Book Value
$39.72 per share

Miscellaneous

Free Float
255,664,000
Market Cap
$82.17 billion
Optionable
Optionable
Beta
0.46

Social Links


Key Executives

  • Reshma KewalramaniReshma Kewalramani
    President, Chief Executive Officer & Director
  • Stuart A. ArbuckleStuart A. Arbuckle
    Chief Operating Officer & Executive Vice President
  • Charles F. WagnerCharles F. Wagner
    Chief Financial Officer & Executive Vice President
  • David Matthew Altshuler
    Chief Scientific Officer & EVP-Global Research
  • Mark Bunnage
    Senior Vice President & Head-Research













VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price forecast for 2023?

15 Wall Street research analysts have issued 12-month target prices for Vertex Pharmaceuticals' shares. Their VRTX share price forecasts range from $280.00 to $374.00. On average, they predict the company's share price to reach $322.79 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2023?

Vertex Pharmaceuticals' stock was trading at $288.78 on January 1st, 2023. Since then, VRTX stock has increased by 11.3% and is now trading at $321.45.
View the best growth stocks for 2023 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our VRTX earnings forecast
.

How can I listen to Vertex Pharmaceuticals' earnings call?

Vertex Pharmaceuticals will be holding an earnings conference call on Tuesday, February 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Tuesday, November, 2nd. The pharmaceutical company reported $3.56 EPS for the quarter, topping the consensus estimate of $2.74 by $0.82. The pharmaceutical company had revenue of $1.98 billion for the quarter, compared to analyst estimates of $1.85 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 29.65% and a net margin of 37.62%. During the same period in the previous year, the company posted $2.36 earnings per share.
Read the conference call transcript
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.80 billion-$8.90 billion, compared to the consensus revenue estimate of $8.77 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.33%), Assenagon Asset Management S.A. (0.29%), Mayflower Financial Advisors LLC (0.28%), Natixis Advisors L.P. (0.18%), Allspring Global Investments Holdings LLC (0.18%) and New York State Teachers Retirement System (0.12%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $321.45.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $82.51 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $12.68 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

The company employs 3,900 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vectrus, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 1/30/2023 by MarketBeat.com Staff